A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *Significant relationship. No financial benefit. ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; and HRS, Heart Rhythm Society. Appendix 3. Abbreviations ACHD adult congenital heart disease AF atrial fibrillation AT atrial tachycardia AV atrioventricular AVNRT atrioventricular nodal reentrant tachycardia AVRT atrioventricular reentrant tachycardia BP blood pressure CTI cavotricuspid isthmus ECG electrocardiogram/electrocardiographic ERC Evidence Review Committee EP electrophysiological Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness GWC guideline writing committee IST inappropriate sinus tachycardia MAT multifocal atrial tachycardia PJRT permanent form of junctional reciprocating tachycardia PSVT paroxysmal supraventricular tachycardia RCT randomized controlled trial SCD sudden cardiac death SVT supraventricular tachycardia VT ventricular tachycardia WPW Wolff-Parkinson-White Appendix 3. Continued